Volume 20 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(5): 766-769
HUANG Jie, LUO Song, LI Jin-ping, LI Xiao-xiong, LIU Cheng-chun, FU Xiao-yan, ZHOU Hua-dong. Safety and efficacy of intravenous tirofiban after endovascular treatment of acute cerebral infarction[J]. Chinese Journal of General Practice, 2022, 20(5): 766-769. doi: 10.16766/j.cnki.issn.1674-4152.002449
Citation: HUANG Jie, LUO Song, LI Jin-ping, LI Xiao-xiong, LIU Cheng-chun, FU Xiao-yan, ZHOU Hua-dong. Safety and efficacy of intravenous tirofiban after endovascular treatment of acute cerebral infarction[J]. Chinese Journal of General Practice, 2022, 20(5): 766-769. doi: 10.16766/j.cnki.issn.1674-4152.002449
shu

Safety and efficacy of intravenous tirofiban after endovascular treatment of acute cerebral infarction

doi: 10.16766/j.cnki.issn.1674-4152.002449
  • 1.

    Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0364

 cstc2019jscx-msxmX0254

  • Received Date: 2021-09-20
    Available Online: 2022-09-05
    Abstract
  •   Objective  To evaluate the safety and efficacy of intravenous tirofiban after endovascular treatment for patients with acute cerebral infarction.  Methods  A total of 152 patients with acute cerebral infarction undergoing endovascular treatment in the Department of Neurology of Daping Hospital, Army Military Medical University from September 2019 to March 2021 were retrospectively included. They were divided into the tirofiban group and control group according to whether tirofiban was injected intravenously after endovascular treatment. The baseline of the two groups was balanced by 1∶ 1 propensity score matching analysis. The main end points included safety and effectiveness. The safety was symptomatic intracranial haemorrhage (sICH), any haemorrhage, recurrence within 90 days and mortality. The effectiveness was National Institutes of Health Stroke Scale (NIHSS) score at discharge and 90-day good prognosis rate (modified Rankin score: 0-2).  Results  A total of 145 patients were included, including 70 in the tirofiban group and 75 in the control group. The NIHSS score of the tirofiban group at discharge [4(2, 13) vs. 11(3, 16), P=0.002] was significantly better than that of the control group. Moreover, there was no significant difference in the incidence of sICH [7(10.0%) vs. 12(16.0%), P=0.284] 90-day prognosis, any bleeding, recurrence and mortality (all P>0.05). Forty-seven pairs were successfully matched by propensity score. There was no significant difference in safety and effectiveness between the two groups (all P>0.05).  Conclusion  Intravenous tirofiban is safe after endovascular treatment of acute cerebral infarction. Pre-matching tirofiban can improve the NIHSS score at discharge of patients with acute cerebral infarction after endovascular treatment, but it has no benefit in the 90-day prognosis rate. After matching, there was no benefit in the good prognosis of tirofiban patients at discharge and 90 days.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    WANG W Z, JIANG B, SUN H X, et al. Prevalence, incidence, and mortality of stroke in China: Results from a nationwide population-based survey of 480 687 adults[J]. Circulation, 2017, 135(8): 759771.
    [2]
    BENJAMIN E J, VIRANI S S, CALLAWAY C W, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association[J]. Circulation, 2018, 137(12): e67-e492.
    [3]
    BERKHEMER O A, FRANSEN P S, BEUMER D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med, 2015, 372(1): 11-20. doi: 10.1056/NEJMoa1411587
    [4]
    BRACARD S, DUCROCQ X, MAS J L, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): A randomised controlled trial[J]. Lancet Neurol, 2016, 15(11): 1138-1147. doi: 10.1016/S1474-4422(16)30177-6
    [5]
    JOVIN T G, CHAMORRO A, COBO E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med, 2015, 372(24): 2296-2306. doi: 10.1056/NEJMoa1503780
    [6]
    MARTO J P, STROMBO D, HAJDU S D, et al. Twenty-four-hour reocclusion after successful mechanical thrombectomy: Associated factors and long-term prognosis[J]. Stroke, 2019, 50(10): 2960-2963. doi: 10.1161/STROKEAHA.119.026228
    [7]
    LI W, LIN L, ZHANG M, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke, 2016, 47(10): 2649-2651. doi: 10.1161/STROKEAHA.116.014413
    [8]
    ZHAO W B, CHE R W, SHANG S Y, et al. Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy[J]. Stroke, 2017, 48(12): 3289-3294. doi: 10.1161/STROKEAHA.117.019193
    [9]
    PAN X, ZHENG D, ZHENG Y, et al. Safety and efficacy of tirofiban combined with endovascular treatment in acute ischemic[J]. Stroke, 2019, 26(8): 1105-1110.
    [10]
    中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. doi: 10.3760/cma.j.issn.1006-7876.2018.09.004

    Neurology branch of Chinese Medical Association, cerebrovascular disease group of Neurology branch of Chinese Medical Association, Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018[J]. Chinese Journal of Neurology, 2018, 51(9): 666-682. doi: 10.3760/cma.j.issn.1006-7876.2018.09.004
    [11]
    朱余友, 王黎, 刘天龙. 大脑中动脉M2段急性闭塞性机械取栓疗效分析[J]. 中华全科医学, 2021, 19(10): 1633-1649. doi: 10.16766/j.cnki.issn.1674-4152.002129

    ZHU Y Y, WANG L, LIU T L. Analysis of therapeutic effect of mechanical thrombectomy for acute occlusion of M2 segment of middle cerebral artery[J]. Chinese general practice, 2021, 19(10): 1633-1649. doi: 10.16766/j.cnki.issn.1674-4152.002129
    [12]
    蔡必扬, 郭洪权, 李华. 关于美国国立卫生研究院卒中量表翻译的警示[J]. 中华神经科杂志, 2017, 50(9): 712. doi: 10.3760/cma.j.issn.1006-7876.2017.09.020

    CAI B Y, GUO H Q, LI H. A warning on the translation of the National Institutes of Health Stroke Scale[J]. Chinese Journal of Neurology, 2017, 50(9): 712. doi: 10.3760/cma.j.issn.1006-7876.2017.09.020
    [13]
    郝佳妮, 屈洪党. 大动脉粥样硬化型脑梗死的诊断与治疗[J]. 中华全科医学, 2019, 17(1): 4-6. http://www.zhqkyx.net/article/id/2033738d-94df-4bf6-8635-7adbd74bad7e

    HAO J N, QU H D. Diagnosis and treatment of large atherosclerotic cerebral infarction[J]. Chinese general practice, 2019, 17(1): 4-6. http://www.zhqkyx.net/article/id/2033738d-94df-4bf6-8635-7adbd74bad7e
    [14]
    ZHU F, HOSSU G, SOUDANT M, et al. Effect of emergent carotid stenting during endovascular therapy for acute anterior circulation stroke patients with tandem occlusion: A multicenter, randomized, clinical trial (TITAN) protocol[J]. Int J Stroke, 2021, 16(3): 342-348. doi: 10.1177/1747493020929948
    [15]
    VON KUMMER R, BRODERICK J P, Campbell B C, et al. The Heidelberg bleeding classification: Classification of bleeding events after ischemic stroke and reperfusion therapy[J]. Stroke, 2015, 46(10): 2981-2986. doi: 10.1161/STROKEAHA.115.010049
    [16]
    YANG M, HUO X, GAO F, et al. Low-dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion[J]. Eur J Neurol, 2020, 27(6): 1056-1061. doi: 10.1111/ene.14170
    [17]
    KELLERT L, HAMETNER C, ROHDE S, et al. Endovascular stroke therapy: Tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome[J]. Stroke, 2013, 44(5): 1453-1455. doi: 10.1161/STROKEAHA.111.000502
    [18]
    ZHANG S, HAO Y G, TIAN X G, et al. Safety of intra-arterial tirofiban administration in ischemic stroke patients after unsuccessful mechanical thrombectomy[J]. J Vasc Interv Radiol, 2019, 30(2): 141-147. doi: 10.1016/j.jvir.2018.08.021
    [19]
    SUN C, LI X, ZHAO Z, et al. Safety and efficacy of tirofiban combined with mechanical thrombectomy depend on ischemic stroke etiology[J]. Front Neurol, 2019, 10: 1100. doi: 10.3389/fneur.2019.01100
    [20]
    WANG X G, ZHANG L Q, LIAO X L, et al. Thrombolysis implementation and monitoring of acute ischemic stroke in China (TIMS-China) investigators. unfavorable outcome of thrombolysis in chinese patients with cardioembolic stroke: A prospective cohort study[J]. CNS Neurosci Ther, 2015, 21: 657-661. doi: 10.1111/cns.12421
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (381) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return